- Home
- ACLX vs RYTM Comparison
ACLX vs RYTM Comparison
Compare ACLX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- RYTM
- Stock Information
- Founded
- ACLX 2015
- RYTM 2008
- Country
- ACLX United States
- RYTM United States
- Employees
- ACLX N/A
- RYTM N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- ACLX Health Care
- RYTM Health Care
- Exchange
- ACLX Nasdaq
- RYTM Nasdaq
- Market Cap
- ACLX 3.6B
- RYTM 3.5B
- IPO Year
- ACLX 2022
- RYTM 2017
- Fundamental
- Price
- ACLX $63.75
- RYTM $56.07
- Analyst Decision
- ACLX Strong Buy
- RYTM Strong Buy
- Analyst Count
- ACLX 14
- RYTM 10
- Target Price
- ACLX $107.67
- RYTM $66.90
- AVG Volume (30 Days)
- ACLX 532.8K
- RYTM 380.5K
- Earning Date
- ACLX 02-26-2025
- RYTM 02-26-2025
- Dividend Yield
- ACLX N/A
- RYTM N/A
- EPS Growth
- ACLX N/A
- RYTM N/A
- EPS
- ACLX N/A
- RYTM N/A
- Revenue
- ACLX $155,818,000.00
- RYTM $112,530,000.00
- Revenue This Year
- ACLX $12.58
- RYTM $66.58
- Revenue Next Year
- ACLX N/A
- RYTM $44.63
- P/E Ratio
- ACLX N/A
- RYTM N/A
- Revenue Growth
- ACLX 230.33
- RYTM 81.55
- 52 Week Low
- ACLX $47.88
- RYTM $35.17
- 52 Week High
- ACLX $107.37
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- ACLX 41.49
- RYTM 42.18
- Support Level
- ACLX $62.38
- RYTM $56.03
- Resistance Level
- ACLX $67.00
- RYTM $58.65
- Average True Range (ATR)
- ACLX 2.82
- RYTM 1.87
- MACD
- ACLX 0.32
- RYTM -0.27
- Stochastic Oscillator
- ACLX 28.44
- RYTM 5.45
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.